1. Scrip
  2. >>Business
  3. >>Deals

How BMS Won A Ten-Day, Three-Way Race To Snap Up RayzeBio

 
• By Alaric DeArment

An SEC filing shows how what started as mostly partnering talks quickly escalated to acquisition discussions, with BMS prevailing over two competing suitors in the end.

Inside BMS's deal to acquire RayzeBio in December • Source: Shutterstock

Bristol Myers Squibb Company looked to speed up its deal to acquire RayzeBio, Inc. as it became clear that two other companies were also in a race to buy it, ultimately leading the drug maker to greatly increase its per-share offering price, a regulatory filing by RayzeBio shows.

The 25 January Securities and Exchange Commission filing goes into detail about how BMS’s deal to acquire the San Diego-based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout

 
• By Andrew McConaghie

Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.

Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact

 
• By Kevin Grogan

Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.

Biogen Joins The Macrocycle Melee With Dayra Tie-Up

 
• By Alaric DeArment

Deal Snapshot: The biotech is joining forces with the Versant Ventures-backed startup, paying $50m upfront to apply its macrocycle peptide platform to immunological diseases.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.